G01N 2800/54
Determining the risk of relapse
G01N2800/54 (Determining the risk of relapse) appears on 166 US grants and 429 published applications in this corpus.
Search patents in G01N- Granted patents
- 166
- Published applications
- 429
- Assignees
- 285
- Inventors
- 1,038
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 7 |
| 2010 | 1 | 12 |
| 2011 | 1 | 18 |
| 2012 | 3 | 22 |
| 2013 | 7 | 21 |
| 2014 | 8 | 27 |
| 2015 | 6 | 34 |
| 2016 | 11 | 33 |
| 2017 | 16 | 27 |
| 2018 | 21 | 30 |
| 2019 | 15 | 35 |
| 2020 | 15 | 23 |
| 2021 | 13 | 27 |
| 2022 | 11 | 17 |
| 2023 | 10 | 26 |
| 2024 | 12 | 25 |
| 2025 | 12 | 27 |
| 2026 | 4 | 15 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Quantitative centrosomal amplification score to predict local recurrence of ductal carcinoma in situ9 Jun 2026US 12,650,430 B2Georgia State University Research Foundation, Inc.
- Method of detecting cancer or cancer cells24 Mar 2026US 12,584,920 B2Panka Cancer Research AG
- Method of predicting response to therapy by assessing tumor genetic heterogeneity10 Mar 2026US 12,571,050 B2Roche Sequencing Solutions, Inc.
- Energetic cancer stem cells (E-CSCS): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy17 Feb 2026US 12,553,092 B2Lunella Biotech, Inc.
- Method of isolating and detecting cancer stem cells28 Oct 2025US 12,455,288 B2
- Methods for Cancer Recurrence Detection and Treatment Thereof10 Sep 2026US 2026/0266837 A1Centre National De La Recherche Scientifique
- Methods of Treating High Risk Multiple Myeloma20 Aug 2026US 2026/0242503 A1Janssen Biotech, Inc.
- Biosignature integration to assess therapy response in breast cancer13 Aug 2026US 2026/0235605 A1Prelude Corporation
- Bladder cancer detection proteins and methods of use thereof13 Aug 2026US 2026/0235607 A1Novelna Inc.
- Biomarkers related to immunotherapy efficacy6 Aug 2026US 2026/0224626 A1Kite Pharma, Inc.
Most cited
By later US patents
- Athletic performance monitoring with body synchronization analysis71US 8,784,274 B12014
- Athletic performance and technique monitoring43US 8,573,982 B12013
- Methods of determining patient response by measurement of Her-334US 8,349,574 B2Laboratory Corporation of America Holdings · 2013
- Prognostic panel for urinary bladder cancer28US 8,293,880 B2University of Southern California · 2012
- Methods of determining efficacy of treatment in a subject having heart failure28US 9,239,333 B2Critical Care Diagnostics, Inc. · 2016